



(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/46 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)
C07K 16/32 (2006.01)

(21) International Application Number:

PCT/US2019/036503

(22) International Filing Date:

11 June 2019 (11.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/684,818 14 June 2018 (14.06.2018) US

(71) Applicant: **BIOATLA, LLC** [US/US]; 11085 Torreyana Road, Suite 100, San Diego, California 92121 (US).

(72) Inventors: **SHORT, Jay, M.**; 12985 Via Esperia, Del Mar, California 92014 (US). **FREY, Gerhard**; 13768 Via Cima Bella, San Diego, California 92129 (US). **CHANG, Hwai, Wen**; 1318 Shadow Hills Drive, San Marcos, California 92069 (US).

(74) Agent: **DUNLEAVY, Kevin, J.**; Mendelsohn Dunleavy, P. C., 1500 John F. Kennedy Blvd., Suite 312, Philadelphia, Pennsylvania 19102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: MULTI-SPECIFIC ANTIBODY CONSTRUCTS



Bi-valent
Hetero-dimer

FIG. 1

(57) Abstract: A multi-specific antibody contains at least one binding site for a cell specific antigen and at least one binding site for a tumor-reactive lymphocyte antigen and a multi-specific antibody including an IgG antibody or fragment thereof that binds to a first antigen; and at least one scFv antibody that binds to a second antigen that is different from the first antigen and is linked to a C terminus of at least one light chain or heavy chain of said IgG antibody or fragment. The multi-specific antibody reversibly binds to at least one of the cell specific antigen and tumor-reactive lymphocyte antigen or the first antigen and the second antigen with a greater affinity at an aberrant condition than at a normal physiological condition. Conjugates of the multi-specific antibodies and methods for generating the multi-specific antibody are also provided.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*